Fosamax and Osteonecrosis of the Jaw: Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Drug-Safety Concerns

The legacy of general health and science information dissemination has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, the communication of pharmaceutical benefits and risks has been a central theme, guiding both clinical practice and patient awareness. As this informational heritage evolved, it increasingly encompassed detailed accounts of adverse effects associated with widely prescribed medications. One such area of focus has been the relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. This transition from general health education to a specific drug-safety concern represents a natural progression in medical discourse.

Bridging to Occupational and Clinical Risk

The pivot now extends further into the realm of occupational exposure, where healthcare professionals, dental practitioners, and pharmaceutical workers may encounter heightened risks due to repeated contact with the compound. This shift reframes the discussion from patient-centered risk communication to a workplace hazard assessment, emphasizing the need for protective measures and monitoring protocols in environments where Fosamax is handled or administered. The bridge between general health literacy and occupational safety thus becomes a critical pathway for ensuring comprehensive risk management across all settings.

Pharmacology and Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ).

Clinical Presentation and Diagnosis of ONJ

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, and exposed bone in the jaw. Diagnosis is typically based on clinical examination and history, with imaging used to assess extent. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors for Fosamax-Associated ONJ

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Biological Plausibility

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, which can impair normal bone remodeling and repair processes in the jawbone. This suppression may compromise the jawbone's ability to heal after minor trauma, such as tooth extraction, leading to necrosis. Multiscale characterization of jawbone tissue has provided information that may help understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high remodeling rate and unique vascular supply may make it particularly susceptible to this adverse effect.

Temporal Association and Dose-Response Evidence

Regarding the timeline between exposure and documented harm, the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Population-level data from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests a dose-response relationship with cumulative exposure.

Adequacy of Warnings and Labeling

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4 "Osteonecrosis of the Jaw" for both Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warning describes the association, risk factors, and recommendations for management, including discontinuation before invasive dental procedures. However, the label also notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, which may understate the risk in real-world settings where longer-term use and dental procedures are common.

Causation Considerations for Affected Patients

For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer, radiation therapy, or other medications. The presence of known risk factors, such as dental procedures or poor oral hygiene, does not preclude Fosamax as a contributing factor, as ONJ is generally associated with these triggers in bisphosphonate users (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The duration of exposure is a key factor, with risk increasing over years of use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Patients who develop ONJ should discontinue Fosamax if severe symptoms develop, and most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Rechallenge with the same or another bisphosphonate may lead to recurrence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Summary of Evidence and Clinical Implications

In summary, Fosamax is associated with a rare but serious risk of ONJ, with evidence supporting a causal relationship through biological plausibility, temporal association, and dose-response data. The prescribing information provides warnings, but the low absolute risk and similarity to placebo in clinical trials may lead to underrecognition in practice. Patients and clinicians should be aware of risk factors and consider dental evaluation before initiating therapy, especially for long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with dental procedures. Fosamax and other bisphosphonates have been linked to ONJ, likely due to suppression of bone turnover. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How common is ONJ in patients taking Fosamax?

ONJ is rare, with absolute risk around 0.05% after 5 years of use. However, risk increases with longer exposure, up to eightfold after 10 years compared to past use. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

What should I do if I develop jaw pain or exposed bone while on Fosamax?

Consult your healthcare provider immediately. They may recommend discontinuing Fosamax and evaluating for ONJ. Most patients experience relief after stopping the drug. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.